PRX-IIE (AT3G52960), Glutaredoxin-S12 (GRX-S12; AT2G20270), and sulfiredoxin (SRX; AT1G31170) were cloned into pET28a (Novagen, Darmstadt, Germany). Forward and reverse primer were designed with NdeI and BamHI restriction sites, respectively (Table S1). The variants C121S, C146S, C121S/C146S, S82D, T108E, and T223E of PRX-IIE were generated by site-directed mutagenesis with specific primers (Table S1). The correctness of all constructs was confirmed by DNA sequencing.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.